A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Sponsor: AbbVie
Listed as NCT02675426, this PHASE3 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by AbbVie, it has been updated 24 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
24 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 19 earlier versions
-
Apr 2022 — May 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — May 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Ankara, Turkey (Türkiye), Astana, Kazakhstan, Austin, United States, Banja Luka, Bosnia and Herzegovina, Berea, South Africa, Berlin, Germany, Bialystok, Poland, Bothell, United States, Brno, Czechia and 138 more location s